Prediction model for hepatitis B e antigen seroconversion in chronic hepatitis B with peginterferon-alfa treated based on a response-guided therapy strategy

Figure 3 Performance of predictive models at baseline, week 12, and week 24 for evaluating hepatitis B e antigen seroconversion (blue bars) and hepatitis B surface antigen loss (pink bars) at 24 wk post-treatment in patients with chronic hepatitis B treated with peginterferon alpha. A: Baseline; B: Week 12; C: Week 24. HBeAg: Hepatitis B e antigen.